SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Piramal Pharma - Quaterly Results

30 Jan 2026 Evaluate
The revenue for the December 2025 quarter is pegged at Rs. 11958.10 millions against Rs. 12483.20 millions recorded during the year-ago period.A humble growth in net profit of 8.51% reported in the quarter ended December 2025 to Rs. 1289.10  millions from Rs. 1188.00 millions.OP of the company witnessed a marginal growth to 2634.00 millions from 2440.40 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202512 202412 % Var 202512 202412 % Var 202503 202403 % Var
Sales 11958.10 12483.20 -4.21 32929.50 35959.10 -8.43 52857.10 43901.10 20.40
Other Income 961.50 247.00 289.27 4790.40 1678.40 185.41 2073.50 2020.60 2.62
PBIDT 2634.00 2440.40 7.93 8176.90 7917.00 3.28 12477.90 8199.80 52.17
Interest 168.40 291.70 -42.27 604.50 840.00 -28.04 1145.60 1071.00 6.97
PBDT 2196.20 2148.70 2.21 7303.00 7077.00 3.19 11332.30 7128.80 58.97
Depreciation 646.90 554.60 16.64 1853.80 1609.20 15.20 2220.90 2052.60 8.20
PBT 1549.30 1594.10 -2.81 5449.20 5467.80 -0.34 9111.40 5076.20 79.49
TAX 260.20 406.10 -35.93 1065.40 1326.50 -19.68 2197.40 1164.00 88.78
Deferred Tax 66.30 -2.20 -3113.64 349.70 27.60 1167.03 203.00 39.20 417.86
PAT 1289.10 1188.00 8.51 4383.80 4141.30 5.86 6914.00 3912.20 76.73
Equity 13258.30 13235.80 0.17 13258.30 13235.80 0.17 13243.50 13229.50 0.11
PBIDTM(%) 22.03 19.55 12.67 24.83 22.02 12.78 23.61 18.68 26.39

Piramal Pharma Share Price

148.90 1.45 (0.98%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×